Evidence-based targets
Endogenous solutions
Portfolio
Our portfolio focuses on harnessing endogenous targets with well-established therapeutic effects.
Pipeline
We have identified two priority targets in the R&D phase which exhibit anti-inflammatory, anxiolytic, antidepressant, and antiseizure effects.
Patients
Our lead targets are based on clinically effective drugs and evidence-based identification of endogenous targets with anti-inanxiolytic, antidepressant, and antiseizure effects.